CN1293041A - Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process - Google Patents
Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process Download PDFInfo
- Publication number
- CN1293041A CN1293041A CN 00114614 CN00114614A CN1293041A CN 1293041 A CN1293041 A CN 1293041A CN 00114614 CN00114614 CN 00114614 CN 00114614 A CN00114614 A CN 00114614A CN 1293041 A CN1293041 A CN 1293041A
- Authority
- CN
- China
- Prior art keywords
- powder
- misgurni anguillicaudati
- medicine
- liver
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A functional food in multiple forms for protecting liver and A new medicine containing polyose, glycoprotein and polypeptide for preventing and curing hepatitis are both prepared from loach. Said food and medicine features sure curative effect and liver-protecting function and stable dosage.
Description
The present invention adopts modern biochemical technology to utilize Misgurni anguillicaudati to prepare functional food for protecting liver and isolate effective natural component of preventing and treating hepatitis from Misgurni anguillicaudati, prevents and treats the medicine of hepatitis in order to preparation.
Misgurni anguillicaudati (Misgurus angillicaudatus Cantor) is the Cobitidae animal, meat or all be used as medicine, and its main effect is that invigorating the spleen and replenishing QI, hepatoprotective remove Huang, heat-clearing and toxic substances removing, dissolving lump and resolving mass.Be recorded in Compendium of Material Medica and the documents such as " Chinese medicine voluminous dictionaries ".Folk remedy is treated diseases such as carbuncle, dysentery, sexual impotence with Misgurni anguillicaudati, also useful Misgurni anguillicaudati looses or Misgurni anguillicaudati soup treatment infectious hepatitis.The method of being introduced according to " Chinese medicine voluminous dictionary " is: after the Misgurni anguillicaudati oven dry, be developed into the end, and each 10 grams, every day three times is in order to the treatment infectious hepatitis.The shortcoming of this method is to need the existing food of existing system, and is edible inconvenient.So far do not see the relevant report that spells out the active component of treatment hepatitis in the Misgurni anguillicaudati as yet.And also do not utilize the function of protecting and nourishing liver food that Misgurni anguillicaudati makes for raw material or the product of Chinese patent medicine to appear on the market.
China is the highest country of incidence of hepatitis rate in the world, and the patient who infects various hepatitis viruss is hundreds of millions of.The present invention is for the fully health care and the medical value of exploitation Misgurni anguillicaudati resource, utilizes that Misgurni anguillicaudati makes that chemical composition is clear and definite, liver protection effect definite, dosage and dosage form is stable, significant new natural biochemical drug and the functional food for protecting liver of preventing and treating hepatitis of prevention effect.
Method of the present invention is: one, the fresh and alive Misgurni anguillicaudati of feeding 1～3 day with clear water is cleaned, and will make 50～500 order fine powders with pulverizer after these Misgurni anguillicaudati dryings, or further is processed into nano level micropowder.Also Misgurni anguillicaudati can be twisted into the meat slurry with meat grinder, add 0～10% protease (as: pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64 etc.), control PH=1～8.5, in 10～50 ℃ of following incubations 5～48 hours, separate, remove residue, 50～500 order fine powders are made with pulverizer in dry back, or this powder further is processed into nano level micropowder.Above-mentioned fine powder is as the primary raw material of functional food for protecting liver.Can be 1～98% Misgurni anguillicaudati dry powder (or its hydrolyzed solution) with liver-protecting function with this content, sneak into following batching: amyloid adjuvant 1～90%, as: flour, starch, oatmeal, Semen Glycines powder, Rhizoma amorphophalli powder, black sesame powder, Semen arachidis hypogaeae powder; Excipient and thickening agent 0～10%, as: starch, dextrin, sodium carboxymethyl cellulose, agar, gelatin, alginate jelly, pectin; Flavoring agent 0～5%, as: Sal, sugar, Mel, milk powder, chocolate, protein sugar, cyclamate, acesulfame potassium, glucide, monosodium glutamate, chicken essence, yeastex, vinegar, vinegar (acid) essence, five spice powder, Fructus Piperis powder, Zanthoxyli Bungeani powder, curry powder, Fructus Capsici powder, Herba Alii fistulosi, Rhizoma Zingiberis powder, Bulbus Allii powder, Herba Menthae; Vitamins 0～2%, as: vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, Citrin; Food coloring 0～3%, as: bean sauce, soy sauce, carotene, caramel color, chocolate pigment, coffee pigment, gardenin, Fructus Citri tangerinae pigment, sunset yellow; Edible essence 0～2%, as: lychee flavor, apple essence, flavoring pineapple essence, strawberry essence, honey peach essence, cocoanut flavour, milk flavour, beef flavor, chicken essence, coffee aroma; Antiseptic 0～1%, as: benzoate, mud moor gold ester, antibacterial peptide, sorbate.The various forms of functional food such as dry powder that can be made into special-shaped sheet, sugar pill, cookies, cake, instant noodles, oral liquid, electuary, medicated porridge paste or use for mixing batter.
Two, fresh and alive Misgurni anguillicaudati was supported 4～96 hours with the distillation water logging, then supersound process; Also Misgurni anguillicaudati can be rubbed with meat grinder, add water homogenate or add 0.1～10% protease (as, pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64 etc.), in 10～50 ℃ of following incubations 5～48 hours, filter control PH=1～8.5.With filtrate by following step process: 1. vacuum concentration to original volume 1/5～1/20 after, add 1～8 times of volume precipitant (as, dehydrated alcohol, acetone etc.), in temperature is-4～5 ℃, rotating speed is that centrifugal 5～30 minutes, inclining supernatant under 4000～1000 rev/mins the condition.2. will precipitate with dehydrated alcohol (or acetone) washing 2～8 times, tell supernatant at every turn again.3. 1. 2. the ethanol of step (or acetone) supernatant is standby in merging.4. a small amount of dissolved in distilled water of precipitation is removed free protein with extractant chloroform-n-butyl alcohol (1: 4) extraction, and water was dialysed 1～4 day to flowing water.Solution in the bag filter of dialysis back is got white cotton-shaped powder through lyophilization.With physics and chemical method analysis, identify that this material is a polysaccharide, mainly to form by fucose and galactose, its molecular weight is 1,000～150,000.5. the ethanol that 2. step is merged (or acetone) supernatant is evaporated to driedly, behind dissolved in distilled water, separates with liquid chromatograph through gel filtration, obtains polysaccharide, glycoprotein and polypeptides matter.The natural active matter of being separated through the zoopery proof has liver protection effect.With the every agent content of these materials by 0.01 gram～10 grams, make the medicine of various dosage forms, as: adding distil water, normal saline or G/W are made oral liquid or injection, or add starch (excipient) 10～50%; Sodium carboxymethyl cellulose (disintegrating agent) 0～15%; Sodium benzoate (antiseptic) 0～1% is made electuary, tablet, unguentum, powder, pill or capsule.Effect of the present invention is as follows: 1.1 couples of carbon tetrachloride (CCl of the mucous liver protection effect of 1 Misgurni anguillicaudati homogenate and Misgurni anguillicaudati
4) cause the inhibitory action of mouse liver injury
Get 48 of male mices, divide equally 6 groups at random: normal control group, normal saline group (NS), Misgurni anguillicaudati homogenate group (LS), Misgurni anguillicaudati mucus group (LM), bifendate group (DDB) and LONGDAN XIEGAN WAN group (LD) by body weight.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% carbon tetrachloride paraffin oil solution of 10ml/kg.Clean food is after 16 hours, broken end is got hematometry serum glutamic pyruvic transminase (ALT) and glutamic oxaloacetic transaminase, GOT (AST) activity, get liver and weigh, detect lipid peroxide (LPO) content in the hepatic tissue, malonaldehyde (MDA) content in the liver weight of unit of account body weight and the hepatic tissue.Result's (table 1) shows that carbon tetrachloride can make transaminase activity in the mice serum and the LPO content in the hepatic tissue significantly raise, and makes the liver enlargement.And that Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus all can obviously suppress in the mice serum that carbon tetrachloride raises the LPO content regulating liver-QI in transaminase activity, the hepatic tissue is swollen.
Table 1 medicine is to carbon tetrachloride (CCl
4) cause inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver MDA liver weight/body weight of x ± SD) of mouse liver injury
/ mgkg-1 * d/UL-1/UL-1/nmolg-1/gkg-1 normal control-188 ± 47 286 ± 38 1.52 25.8 ± 3.7 35.2 ± 5.1 NS+CCl4 150 * 6 896 ± 33##, 579 ± 87##, 0.65 40.6 ± 4.5##, 47.2 ± 1.8## LS+CCl4 150 * 6 439 ± 97
*358 ± 94
*0.82 35.2 ± 4.1
*43.2 ± 3.3
*LM+CCl4 150 * 6 533 ± 48
*446 ± 60
*0.84 36.5 ± 5.0
*45.1 ± 3.9
*DDB+CCl4 150 * 6 276 ± 23
*288 ± 26
*1.04 39.7 ± 3.5 40.6 ± 6.5
*LD+CCl4 150 * 6 457 ± 79
*401 ± 67
*0.88 29.6 ± 3.1
*41.8 ± 3.4
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.011.2 causes the inhibitory action of mouse liver injury to thioacetamide (TAA)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 1.2.Except that the normal control group, all the other 6 groups after last administration in the 6th day 2 hours, weigh earlier, the dosage lumbar injection 0.2% thioacetyl amine aqueous solution by 80ml/kg makes it to poison again.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and detects LPO content, MDA content in the heavy and hepatic tissue of the liver of unit of account body weight.Result's (table 2) illustrates that thioacetamide can make transaminase activity in the mice serum and the LPO content in the hepatic tissue significantly raise, and makes the liver enlargement.And that Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus and extract thereof all can obviously suppress in the mice serum that thioacetamide raises the LPO content regulating liver-QI in transaminase activity, the hepatic tissue is swollen.
Table 2 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver MDA liver weight/body weight of x ± SD) of mouse liver injury to thioacetamide
/ mgkg-1 * d/UL-1/UL-1/nmolg-1/gkg-1 normal control-188 ± 47 286 ± 38 1.52 25.8 ± 3.7 35.2 ± 5.1NS+TAA 150 * 6 937 ± 22##, 693 ± 78##, 0.74 41.6 ± 2.8##, 50.8 ± 2.5##LS+TAA 150 * 6 541 ± 26
*436 ± 92
*0.81 32.6 ± 4.0
*45.9 ± 4.3
*LM+TAA 150 * 6 638 ± 14
*528 ± 18
*0.83 34.3 ± 3.5
*45.6 ± 3.2
*DDB+TAA 150 * 6 306 ± 13
*297 ± 25
*0.97 40.2 ± 3.6 45.8 ± 2.5
*LD+TAA 150 * 6 460 ± 49
*421 ± 68
*0.92 30.8 ± 3.2
*43.7 ± 4.5
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.01
It is to study hepatic effect and mechanism of action pathological model commonly used at present that carbon tetrachloride and thioacetamide cause hepatic injury.Heavy dose of attack can cause serious hepatocellular damage, causes energy metabolism impairment, and the liver plasma membrane permeability is increased, and the transaminase is released in the blood because of huge Concentraton gradient in the cell.Therefore, the serum aminotransferase activity rising is the impaired sensitive indicator of hepatocyte.Misgurni anguillicaudati homogenate is observed in this work and the Misgurni anguillicaudati mucus can both significantly suppress the caused mice serum transaminase rising of these two kinds of model things.Also observe two kinds of model things simultaneously and can both cause that lipid peroxide contents increases regulating liver-QI swelling in the murine liver tissue, Misgurni anguillicaudati homogenate and Misgurni anguillicaudati mucus can significantly suppress the rising of these indexs.As seen, Misgurni anguillicaudati and mucus thereof have many-sided inhibitory action to experimental hepatic injury.2.1 couples of carbon tetrachloride (CCl of the liver protection effect of 2 Misgurni anguillicaudati polysaccharide
4) cause the inhibitory action of mouse liver injury
40 of mices, male and female half and half, be divided into 5 groups at random: normal control group, normal saline (NS) group, Misgurni anguillicaudati polysaccharide high dose (HPS) group, Misgurni anguillicaudati polysaccharide low dosage (LPS) group and bifendate (DDB) group, gastric infusion dosage and consecutive days are undertaken by table 3.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% carbon tetrachloride paraffin oil solution of 10ml/kg.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and the liver of unit of account body weight is heavy.Result's (table 3) shows that carbon tetrachloride can make the transaminase activity in the mice serum significantly raise, and makes the liver enlargement.And that the Misgurni anguillicaudati polysaccharide can obviously suppress in the mice serum that carbon tetrachloride raises the transaminase activity regulating liver-QI is swollen.
Table 3 medicine is to carbon tetrachloride (CCl
4) cause inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver weight/body weight of x ± SD) of mouse liver injury
/ mgkg-1 * d/UL-1/UL-1/gkg-1 normal control-120 ± 31 266 ± 39 2.22 35.2 ± 5.1NS+CCl4 150 * 6 727 ± 19##, 510 ± 29##, 0.70 47.2 ± 1.8##HPS+CCl4 300 * 6 352 ± 38
*347 ± 75
*0.99 42.7 ± 3.8
*LPS+CCl4 150 * 6 438 ± 21
*426 ± 74
*0.97 43.2 ± 3.3
*DDB+CCl4 150 * 6 270 ± 23
*278 ± 16
*1.03 40.6 ± 6.5
*LD+CCl4 150 * 6 457 ± 79
*401 ± 67
*0.88 41.8 ± 3.4
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.012.2 causes the inhibitory action of mouse liver injury to thioacetamide (TAA)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 2.1.Except that the normal control group,, weigh after 2 hours in last administration in the 6th day for all the other 6 groups, make it to poison by the dosage lumbar injection 0.2% thioacetyl amine aqueous solution of 80ml/kg.Clean food is after 16 hours, and broken end is got hematometry Serum ALT and AST, gets liver and weighs, and the liver of unit of account body weight is heavy.Result's (table 4) illustrates that thioacetamide can make the transaminase activity in the mice serum significantly raise, and makes the liver enlargement.And that the Misgurni anguillicaudati polysaccharide can obviously suppress in the mice serum that thioacetamide raises the transaminase activity regulating liver-QI is swollen.
Table 4 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST AST/ALT liver weight/body weight of x ± SD) of mouse liver injury to thioacetamide
/ mgkg-1 * d/UL-1/UL-1/gkg-1 normal control-120 ± 31 266 ± 39 2.22 35.2 ± 5.1NS+TAA 150 * 6 737 ± 22##, 471 ± 29##, 0.64 50.8 ± 2.5##HPS+TAA 300 * 6 368 ± 15
*424 ± 18
*1.15 43.6 ± 2.2
*LPS+TAA 150 * 6 414 ± 32
*388 ± 48
*0.94 45.9 ± 4.3
*DDB+TAA 150 * 6 306 ± 13
*297 ± 25
*0.97 45.8 ± 2.5
*LD+TAA 150 * 6 460 ± 49
*421 ± 68
*0.92 43.7 ± 4.5
*Compare with normal group: #P＜0.05, compare with group ##P＜0.01:
*P＜0.05,
*P＜0.012.3 causes the inhibitory action of mouse liver injury to ANIT (NAIT)
Mice group, route of administration, dosage, administration number of times and consecutive days are all identical with 2.1.Except that the normal control group, all the other 6 groups after last administration in the 6th day 2 hours, weigh, irritate stomach 15mg/ml ANIT salad oil solution by the dosage of 80ml/kg and make it to poison.Clean food 16 hours, broken end is got hematometry Serum ALT and AST, gets liver and gall and weighs, and the liver and gall of unit of account body weight are heavy.Result's (table 5) illustrates that NAIT can make transaminase activity and icteric index in the mice serum significantly raise, and makes the liver enlargement.And the Misgurni anguillicaudati polysaccharide can suppress obviously that transaminase activity and icteric index raise in the mice serum that NAIT causes, and the liver swelling degree and the jaundice that can significantly reduce mice are smouldered.
Table 5 medicine causes inhibitory action (n=8, the group dosage Serum ALT serum AST liver weight/body weight gallbladder weight/body weight icteric index of x ± SD) of mouse liver injury to ANIT (NAIT)
/ mgkg-1 * d/UL-1/UL-1/gkg-1/gkg-1 normal control-120 ± 31 266 ± 39 35.2 ± 5.1 0.41 ± 0.12 9.3 ± 1.16NS+NAIT 150 * 6 787 ± 13##, 529 ± 9##, 49.4 ± 4.4##, 1.85 ± 0.95##, 29.5 ± 1.60##HPS+NAIT 300 * 6 319 ± 20
*353 ± 29
*45.5 ± 1.9
*0.92 ± 0.91
*15.7 ± 1.07
*LPS+NAIT 150 * 6 350 ± 32
*377 ± 26
*45.3 ± 2.1
*1.41 ± 0.90 17.8 ± 1.31
*DDB+NAIT 150 * 6 243 ± 11
*286 ± 77
*49.7 ± 6.9
*0.88 ± 0.39
*18.5 ± 1.06
*LD+NAIT 150 * 6 460 ± 49
*421 ± 68
*43.7 ± 4.5
*1.63 ± 0.97 27.3 ± 1.52 with normal group relatively: #P＜0.05, ##P＜0.01 and group relatively:
*P＜0.05,
*P＜0.01
Comprehensive The above results: making health food or therefrom extract molecular weight with Misgurni anguillicaudati is 1; 000～150; 000 natural polysaccharide, glycoprotein and polypeptides matter show that through animal experiment study it has antiinflammatory, transaminase lowering, removes jaundice and liver-protective effect.Adult's taking dose was 0.1 milligram～100 gram/days.
The preparation example:
Example 1. Misgurni anguillicaudati liver-protecting tablet: get 5～6 kilograms of fresh and alive Misgurni anguillicaudatis, fed 1 day, clean, will make 100 order fine powders with pulverizer after these Misgurni anguillicaudati dryings with clear water.Press following pharmaceutical formulation: Misgurni anguillicaudati dry powder 880 grams, starch 100 grams, sodium carboxymethyl cellulose 17.5 grams, Herba Menthae 2 grams, sodium benzoate 0.5 restrains, and after the adding distil water pelletize, is pressed into the Misgurni anguillicaudati hepatoprotective abnormity sheet of 1 gram/grain.
Example 2. Misgurni anguillicaudati HUAGAN JIAONANG: get 5～6 kilograms of fresh and alive Misgurni anguillicaudatis, fed 1 day, clean, will make 150 order fine powders with pulverizer after these Misgurni anguillicaudati dryings with clear water.Press following pharmaceutical formulation: Misgurni anguillicaudati dry powder 900 grams, starch 80 grams, sodium carboxymethyl cellulose 19.5 grams, sodium benzoate 0.5 gram after the adding distil water pelletize, incapsulates by 0.5 gram/grain, and the Misgurni anguillicaudati HUAGAN JIAONANG is made in capping.
Example 3. Misgurni anguillicaudati polyoses oral liquids: with 3 kilograms of fresh and alive Misgurni anguillicaudatis, supported 24 hours with the distillation water logging, supersound process is filtered then.With adding the anhydrous alcohol of 4 times of volumes behind filtrate vacuum concentration to 1/8 volume, be 0 ℃ in temperature, rotating speed is that centrifugal 10 minutes, inclining supernatant under 7000 rev/mins the condition.Precipitation is told supernatant with anhydrous alcohol washing 3 times, and it is standby to merge whole supernatant.The a small amount of dissolved in distilled water of precipitation is removed free protein with extractant chloroform-n-butyl alcohol (1: 4) extraction, and water was to water dialysis 1～4 day.Solution in the bag filter of dialysis back is obtained including the white cotton-shaped powdered rubber of polysaccharide, glycoprotein and polypeptide class through lyophilization.By following pharmaceutical formulation: Misgurni anguillicaudati polysaccharide 10 grams, lychee flavor 1.5 grams, sodium carboxymethyl cellulose 3.5 grams, Herba Menthae 1 gram, Saccharum Sinensis Roxb. 5 grams, acetic acid 2 grams, 1000 milliliters of distilled water, mixing, behind the pasteurization, capping is distributed into 10 milliliters/Misgurni anguillicaudati polyoses oral liquid.
Claims (15)
1. method for preparing functional food for protecting liver, it is characterized in that: clean with the fresh and alive Misgurni anguillicaudati that clear water was fed 1～3 day, to make 50 orders after these Misgurni anguillicaudati dryings to nano level fine powder, can be 1～98% thin dry powder of Misgurni anguillicaudati with liver-protecting function with this content, sneaking into batching and making the food that hepatoprotective becomes function.
2. method for preparing functional food for protecting liver, it is characterized in that: Misgurni anguillicaudati is twisted into the meat slurry with meat grinder, add 0～10% protease, control PH=1～8.5, in 10～50 ℃ of following incubations 5～48 hours, will make after the hydrolyzed solution drying of telling 50 orders to nano level fine powder, can be 1～98% thin dry powder of Misgurni anguillicaudati with liver-protecting function with this content, sneaking into prepares burden makes the food that hepatoprotective becomes function.
3. according to a kind of method for preparing functional food for protecting liver of claim 2 indication, it is characterized in that: described protease can be pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64.
4. adopt the functional food for protecting liver of Misgurni anguillicaudati preparation, it is characterized in that: the food of liver-protecting function is to be that the thin dry powder of 1～98% Misgurni anguillicaudati is as primary raw material with content, and sneak into following batching: amyloid adjuvant 1～90%, excipient and thickening agent 0～10%, flavoring agent 0～5%, vitamins 0～2%, food coloring 0～3%, edible essence 0～2%, antiseptic 0～1% is made the food of liver-protecting function.
5. according to the functional food for protecting liver of the employing Misgurni anguillicaudati of claim 4 indication preparation, it is characterized in that: said functional food for protecting liver can be special-shaped sheet, sugar pill, cookies, cake, instant noodles, oral liquid, electuary, medicated porridge is stuck with paste or the dry powder used for mixing batter.
6. according to the functional food for protecting liver of the Misgurni anguillicaudati of claim 4 indication preparation, it is characterized in that: the amyloid adjuvant of indication is: flour, starch, oatmeal, Semen Glycines powder, Rhizoma amorphophalli powder, black sesame powder, Semen arachidis hypogaeae powder; Excipient and thickening agent are: starch, dextrin, sodium carboxymethyl cellulose, agar, gelatin, alginate jelly, pectin; Flavoring agent is: Sal, sugar, Mel, milk powder, chocolate, protein sugar, cyclamate, acesulfame potassium, glucide, monosodium glutamate, chicken essence, yeastex, acetic acid, five spice powder, Fructus Piperis powder, Zanthoxyli Bungeani powder, curry powder, Fructus Capsici powder, Herba Alii fistulosi, Rhizoma Zingiberis powder, Bulbus Allii powder, Herba Menthae; Vitamins is: vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, Citrin; Food coloring is: bean sauce, soy sauce, carotene, caramel color, chocolate pigment, coffee pigment, gardenin, Fructus Citri tangerinae pigment, sunset yellow; Edible essence is: lychee flavor, apple essence, flavoring pineapple essence, strawberry essence, honey peach essence, cocoanut flavour, milk flavour, beef flavor, chicken essence, coffee aroma; Antiseptic is: benzoate, mud moor gold ester, antibacterial peptide, sorbate.
7. method for preparing the medicine of preventing and treating hepatitis is characterized in that: fresh and alive Misgurni anguillicaudati was supported 4～96 hours with the distillation water logging, and supersound process is filtered then; With filtrate by following step process: 1. vacuum concentration to original volume 1/5～1/20 after, the precipitant dehydrated alcohol that adds 1～8 times of volume is-4～5 ℃ in temperature, and rotating speed is under 4000～1000 rev/mins the condition, centrifugal 5～30 minutes, inclining supernatant; 2. will precipitate and use absolute ethanol washing 2～8 times, tell supernatant at every turn again; 3. 1. 2. the ethanol supernatant of step is standby in merging; 4. precipitation is used a small amount of dissolved in distilled water, removes free protein with 1: 4 chloroform-n-butanol extraction of extractant, and water was dialysed 1～4 day to flowing water; Solution in the bag filter of dialysis back is obtained white cotton-shaped powder through lyophilization; 5. the ethanol supernatant that 2. step is merged is evaporated to dried, behind dissolved in distilled water, separates with liquid chromatograph through gel filtration, obtains polysaccharide, glycoprotein and polypeptides matter; With the every agent contents of these materials by 0.01 gram～10 grams, in addition adjuvant is made and is prevented and treated the medicine that hepatitis is prevented and treated hepatitis.
8. prevent and treat the method for the medicine of hepatitis according to the preparation of claim 7 indication, it is characterized in that: the precipitant of indication can also be an acetone.
9. a method for preparing the medicine of preventing and treating hepatitis is characterized in that: fresh and alive Misgurni anguillicaudati was supported 4～96 hours with the distillation water logging, Misgurni anguillicaudati is rubbed with meat grinder, add water homogenate, filter; With filtrate by following step process: 1. vacuum concentration to original volume 1/5～1/20 after, the precipitant dehydrated alcohol that adds 1～8 times of volume is-4～5 ℃ in temperature, and rotating speed is under 4000～1000 rev/mins the condition, centrifugal 5～30 minutes, inclining supernatant; 2. will precipitate and use absolute ethanol washing 2～8 times, tell supernatant at every turn again; 3. 1. 2. the ethanol supernatant of step is standby in merging; 4. precipitation is used a small amount of dissolved in distilled water, removes free protein with 1: 4 chloroform-n-butanol extraction of extractant, and water to flowing water dialysis 1～4 day, is got white cotton-shaped powder with the solution in the bag filter of dialysis back through lyophilization; 5. the ethanol supernatant that 2. step is merged is evaporated to dried, behind dissolved in distilled water, separates with liquid chromatograph through gel filtration, obtains polysaccharide, glycoprotein and polypeptides matter, and adjuvant is made and prevented and treated the medicine that hepatitis is prevented and treated hepatitis in addition.
10. prevent and treat the method for the medicine of hepatitis according to the preparation of claim 9 indication, it is characterized in that: the precipitant of indication can also be an acetone.
11. method for preparing the medicine of preventing and treating hepatitis, it is characterized in that: fresh and alive Misgurni anguillicaudati was supported 4～96 hours with the distillation water logging, Misgurni anguillicaudati is rubbed with meat grinder, add 0.1～10% protease, control PH=1～8.5, in 10～50 ℃ of following incubations 5～48 hours, filter, with filtrate by following step process: 1. vacuum concentration to original volume 1/5～1/20 after, the precipitant dehydrated alcohol that adds 1～8 times of volume is-4～5 ℃ in temperature, and rotating speed is under 4000～1000 rev/mins the condition, centrifugal 5～30 minutes, inclining supernatant; 2. will precipitate and use absolute ethanol washing 2～8 times, tell supernatant at every turn again; 3. 1. 2. the ethanol supernatant of step is standby in merging.4. precipitation is used a small amount of dissolved in distilled water, removes free protein with 1: 4 chloroform-n-butanol extraction of extractant, and water to flowing water dialysis 1～4 day, is got white cotton-shaped powder with the solution in the bag filter of dialysis back through lyophilization; 5. the ethanol supernatant that 2. step is merged is evaporated to dried, behind dissolved in distilled water, separates with liquid chromatograph through gel filtration, obtains polysaccharide, glycoprotein and polypeptides matter, and adjuvant is made and prevented and treated the medicine that hepatitis is prevented and treated hepatitis in addition.
12. the method according to the preparation of claim 11 indication prevents and treats the medicine of hepatitis is characterized in that: the precipitant of indication can also be an acetone.
13. the method according to a kind of preparation of claim 11 indication prevents and treats the medicine of hepatitis is characterized in that: described protease is pepsin, trypsin, papain, Streptothrix protease E, protease V8 or E.C. 3.4.21.64.
14. medicine of preventing and treating hepatitis, it is characterized in that: will separate the white cotton-shaped powdered rubber that includes polysaccharide, glycoprotein and polypeptide class that obtains from the processing of Misgurni anguillicaudati filtrate and restrain～10 every agent contents that restrain by 0.01, adding distil water, normal saline, G/W are made oral liquid, injection.
15. a medicine of preventing and treating hepatitis is characterized in that: will separate the polysaccharide, glycoprotein and the polypeptides matter that obtain from the processing of Misgurni anguillicaudati filtrate and restrain～10 every agent contents that restrain, and add excipient: starch 10～50% by 0.01; Disintegrating agent: sodium carboxymethyl cellulose 0～15%; Antiseptic: sodium benzoate 0～1% is made electuary, tablet, unguentum, powder, pill or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114614 CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00114614 CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03103933 Division CN1217672C (en) | 2000-06-05 | 2000-06-05 | Medicine for preventing and curing hepatitis prepared from mudlump and its preparing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1293041A true CN1293041A (en) | 2001-05-02 |
| CN1116047C CN1116047C (en) | 2003-07-30 |
Family
ID=4584267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00114614 Expired - Fee Related CN1116047C (en) | 2000-06-05 | 2000-06-05 | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1116047C (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897404A (en) * | 2010-05-25 | 2010-12-01 | 湖南农业大学 | Preparation method of loach dried noodles |
| CN101946895A (en) * | 2010-09-02 | 2011-01-19 | 山东商业职业技术学院 | Functional food taking loach as main material and preparation method thereof |
| CN102771704A (en) * | 2012-06-18 | 2012-11-14 | 胡侠 | Special loach noodles for arthritis patients and manufacture method of special loach noodles |
| CN103394071A (en) * | 2013-07-29 | 2013-11-20 | 四川龙王洞生态农业开发有限公司 | Method for producing giant salamander polypeptide powder liver protection capsules |
| CN104738700A (en) * | 2015-02-16 | 2015-07-01 | 湖南鳅祥生物科技实业有限公司 | Liver-protecting loach product and preparation method thereof |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN108576825A (en) * | 2018-04-11 | 2018-09-28 | 崔勇 | A kind of loach protein powder and the preparation method and application thereof, for reducing the food and drug of blood fat or cholesterol or blood pressure |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN112587647A (en) * | 2020-12-22 | 2021-04-02 | 中国海洋大学 | Application of roe glycoprotein in liver protection product |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
-
2000
- 2000-06-05 CN CN 00114614 patent/CN1116047C/en not_active Expired - Fee Related
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897404A (en) * | 2010-05-25 | 2010-12-01 | 湖南农业大学 | Preparation method of loach dried noodles |
| CN101897404B (en) * | 2010-05-25 | 2013-04-24 | 湖南农业大学 | Preparation method of loach dried noodles |
| CN101946895A (en) * | 2010-09-02 | 2011-01-19 | 山东商业职业技术学院 | Functional food taking loach as main material and preparation method thereof |
| CN101946895B (en) * | 2010-09-02 | 2012-06-27 | 山东商业职业技术学院 | Functional food taking loach as main material and preparation method thereof |
| US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN102771704A (en) * | 2012-06-18 | 2012-11-14 | 胡侠 | Special loach noodles for arthritis patients and manufacture method of special loach noodles |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN103394071A (en) * | 2013-07-29 | 2013-11-20 | 四川龙王洞生态农业开发有限公司 | Method for producing giant salamander polypeptide powder liver protection capsules |
| CN103394071B (en) * | 2013-07-29 | 2015-06-03 | 四川龙王洞生态农业开发有限公司 | Method for producing giant salamander polypeptide powder liver protection capsules |
| US10407393B2 (en) | 2014-08-28 | 2019-09-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10822307B2 (en) | 2014-08-28 | 2020-11-03 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| CN104738700B (en) * | 2015-02-16 | 2017-11-21 | 湖南鳅祥生物科技实业有限公司 | A kind of loach protect liver product and preparation method thereof |
| CN104738700A (en) * | 2015-02-16 | 2015-07-01 | 湖南鳅祥生物科技实业有限公司 | Liver-protecting loach product and preparation method thereof |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| CN108576825A (en) * | 2018-04-11 | 2018-09-28 | 崔勇 | A kind of loach protein powder and the preparation method and application thereof, for reducing the food and drug of blood fat or cholesterol or blood pressure |
| CN112587647B (en) * | 2020-12-22 | 2023-02-17 | 中国海洋大学 | Application of fish egg glycoprotein in liver protection product |
| CN112587647A (en) * | 2020-12-22 | 2021-04-02 | 中国海洋大学 | Application of roe glycoprotein in liver protection product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1116047C (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1116047C (en) | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process | |
| US10278994B2 (en) | Method for the preparation of skipjack tuna extract having uric acid-lowering effect and the use thereof | |
| CN112521524B (en) | Composition for synergistically reducing blood sugar by using lycium barbarum polysaccharide and acaudina molpadioides functional peptide | |
| CN114502184A (en) | Pharmaceutical and food compositions for the prevention and treatment of coronavirus infection comprising Elaeagnus dulcis extract | |
| CN105233253B (en) | A kind of compound Chinese medicinal preparation for treating swine fever hyperpyrexia disease and preparation method thereof | |
| CN106074493A (en) | The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract | |
| CN101433595A (en) | Desertliving cistanche alcohol extract as well as preparation method and use thereof | |
| CN1217672C (en) | Medicine for preventing and curing hepatitis prepared from mudlump and its preparing | |
| CN110801456A (en) | Application of cordycepin in preparation of liver protection product | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| WO1993013787A1 (en) | Immunopotentiating agent | |
| CN101559166B (en) | Ophiopogon japonicus extract, preparation method and hypoglycemic application thereof | |
| CN109833366B (en) | Application of traditional Chinese medicine composition in preparation of medicine for improving immunity | |
| CN114288361A (en) | Lonicera and Forsythia detoxifying mixture and preparation method thereof | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| JP2022511544A (en) | Chinese herbal medicine composition for bowel movement, its preparation method and its use | |
| CN104383287A (en) | Composition for increasing immunity | |
| CN1424052A (en) | Medicine for treating chronic hepatitis B | |
| US6582733B1 (en) | Composition for the treatment of hepatitis including HCV | |
| EP0970968A1 (en) | Pharmacologically active substance | |
| KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus | |
| CN104000969B (en) | A kind of Chinese materia medica preparation for treating children's intestines system lymphonodi abdominales inflammation | |
| CN108542940A (en) | A kind of Chinese medicine composition prepare prevent and/or treatment hand-foot-and-mouth disease drug in application | |
| CN116602405B (en) | Use of a composition comprising black pepper extract for the preparation of a product for promoting muscle protein synthesis and for alleviating and/or eliminating inflammation | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |